NASDAQ: DERMJourney Medical Corp Stock
$6.31+0.11 (+1.77%)
Updated May 29, 2026
DERM Price
$6.31
Fair Value Price
-$5.77
Market Cap
$173.74M
52 Week Low
$4.31
52 Week High
$9.56
P/E
-17.05x
P/B
5.64x
P/S
1.98x
PEG
N/A
Dividend Yield
N/A
Revenue
$64.68M
Earnings
-$9.59M
Gross Margin
65.4%
Operating Margin
-9.01%
Profit Margin
-14.8%
Debt to Equity
1.97
Operating Cash Flow
-$7M
Beta
0.65
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
DERM Overview
Journey Medical Corporation develops and commercializes pharmaceuticals to treat dermatological conditions in the U.S. Products include Qbrexza, Accutane, Targadox, Ximino, and Exelderm. Journey Medical also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. Formerly known as Coronado Dermatology, Inc., the company was incorporated in 2014 and is headquartered in Scottsdale, AZ.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DERM's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
DERM
Ranked#19 of 52
Ranked#19 of 52
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $36.02 | A | |
| $158.30 | A | |
| $16.26 | A |
Be the first to know about important DERM news, forecast changes, insider trades & much more!
DERM News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DERM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DERM ($6.31) is overvalued by 209.28% relative to our estimate of its Fair Value price of -$5.77 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
DERM ($6.31) is not significantly undervalued (209.28%) relative to our estimate of its Fair Value price of -$5.77 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
DERM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more DERM due diligence checks available for Premium users.
Valuation
DERM fair value
Fair Value of DERM stock based on Discounted Cash Flow (DCF)
Price
$6.31
Fair Value
-$5.77
Undervalued by
209.28%
DERM ($6.31) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DERM ($6.31) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DERM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DERM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-17.05x
Industry
11.49x
Market
23.22x
DERM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.64x
Industry
1.55x
DERM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DERM's financial health
Profit margin
Revenue
$16.0M
Net Income
-$2.2M
Profit Margin
-14%
DERM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
DERM's profit margin (-14.8%) has... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$91.5M
Liabilities
$60.7M
Debt to equity
1.97
DERM's short-term assets ($64.97M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DERM's short-term assets ($64.97M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DERM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$2.9M
Investing
$0.0
Financing
$220.0k
DERM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DERM vs Pharmaceutical Stocks
Journey Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.